![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, September 18, 2013 5:10:36 PM
In that piece it was highlighted that CTIX had only ~1/3-1/2 the market cap. of other companies entering trials at Harvard. CTIX was greatly undervalued compared to its peers. Moreover the other companies drugs had nothing near the potential of Kevetrin. If I recall it correctly the others were all cancer drugs but for more rare indications. Nowhere near a drug that could potentially treat 1/2 the known cancers and be a MAJOR SCIENTIFIC BREAKTHOUGH!
IMO, in terms of pps/market cap the company gets little to no credit for the fact that the K trial is being ran at Harvard. Not much value is given to the fact that Kevetrin can potentially be a treatment for so many cancers, nothing for future potential sells even greatly discounted by the fact that is still in p1. No hype whatsoever! This is if you just factor in Kevetrin excluding the rest of the pipeline!
There is something hanging-over this company that in my many years here I cannot put my finger on. The stock hovers around $2 now because of a small float and retail longs that are true believers. I recall when I read that article I thought based on this CTIX should have at least a 1 billion dollar market cap even before the Harvard trial begins! If you don't believe this is possible you may have been invested in CTIX too long, last part is a joke, sort of?
IMO, just Ranting
ps I am out in the woods working this week if know one else posts that article I will look for it this weekend.
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
FEATURED Mawson Finland Provides Update on Exploration Activities at Rajapalot • Aug 21, 2024 9:06 AM
All Things Mobile Analytic, Inc. Reports Major Growth with Over $11 Million in Revenue • ATMH • Aug 22, 2024 7:19 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM
Avant Technologies to Implement Robust Cybersecurity Measures for AI-Driven Healthcare Solutions • AVAI • Aug 21, 2024 8:00 AM
HealthLynked Corp. Announces Second Quarter and First Half 2024 Results: Continued Cost Reductions Set the Stage for Strategic Shift to App-Based Technology Services • HLYK • Aug 16, 2024 8:00 AM
PickleJar Announces Official Name Change and New Ticker Symbol • NREG • Aug 15, 2024 2:23 PM